R&D tax incentive rebate received
Filed with ASX · · 2 pages · English
Sydney, 20 October 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that it has received a research and development (R&D) tax Incentive rebate of $4,165,401.66 from the Australian Tax Office for the 2022 financial year. The R&D tax incentive is an Australian federal government program under which companies receive cash refunds for eligible research and development e
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- ACW clinical biomarker study webcast presentation
- ACW announces positive Alzheimers Disease clinical results
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW Appendix 4E and 2022 Annual Report
- ACW CEO presentation to Spark Plus Aust Equities Day
Later from Actinogen Medical
- First patient treated in XanaCIDD Phase 2 Depression Trial
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
- Appendix 4D & Half-Year Financial Statements
- ACW AD trial amendment and Clinical Science Forum slides
- Quarterly Activity Report & Appendix 4C
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical